Aragon Pharmaceuticals, Inc. et al v. Sandoz Inc.
| Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California and Sloan-Kettering Institute for Cancer Research |
| Sandoz Inc. |
| 1:2022cv00678 |
| May 25, 2022 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 14, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 8 STIPULATION TO EXTEND TIME for Sandoz to answer, move or otherwise respond to the Complaint to August 30, 2022 - filed by Sandoz Inc.. (Gattuso, Dominick) |
SO ORDERED, re #8 STIPULATION TO EXTEND TIME for Sandoz to answer, move or otherwise respond to the Complaint to August 30, 2022, filed by Sandoz Inc. Reset Answer Deadlines: Sandoz Inc. answer due 8/30/2022. Ordered by Judge Colm F. Connolly on 6/14/2022. (kmd)
|
| Filing 7 SUMMONS Returned Executed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., The Regents of the University of California, Sloan-Kettering Institute for Cancer Research. Sandoz Inc. served on 6/1/2022, answer due 6/22/2022. (Blumenfeld, Jack) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:22-cv-00678-CFC, 1:22-cv-00688-CFC, 1:22-cv-00696-CFC (rjb) |
| Filing 6 Summons Issued as to Sandoz Inc. on 5/24/2022. (srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. The Regents of the University of California has no parent corporation. Sloan-Kettering Institute for Cancer Research has no parent corporation. - Filed by Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan-Kettering Institute for Cancer Research, and The Regents of the University of California. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,445,507 B2 ;8,802,689 B2 ;9,388,159 B2 ;9,481,663 B2 ;9,987,261 B2. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 14, 2022. Date of Expiration of Patent: U.S. Patent No. 8,445,507 expires on September 15, 2030. Patent Nos. 8,802,689; 9,388,159; and 9,987,261 expire on March 27, 2027. U.S. Patent 9,481,663 expires on June 4, 2033.Thirty Month Stay Deadline: 8/14/2025. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT filed against Sandoz Inc. ( Filing fee $ 402, receipt number ADEDC-3880991.) - filed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., The Regents of the University of California, and Sloan-Kettering Institute for Cancer Research. (Attachments: #1 Exhibit A-E, #2 Civil Cover Sheet)(srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
